Reduced prevalence of SARS-CoV-2 infection in ABO blood group O

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Mike Bogetofte Barnkob, University of Southern Denmark
  • ,
  • Anton Pottegård, University of Southern Denmark
  • ,
  • Henrik Støvring
  • Thure Mors Haunstrup, Aalborg University
  • ,
  • Keld Homburg, Sjællands Universitetshospital
  • ,
  • Rune Larsen, Sjællands Universitetshospital
  • ,
  • Morten Bagge Hansen, Rigshospitalet
  • ,
  • Kjell Titlestad, University of Southern Denmark
  • ,
  • Bitten Aagaard, Aalborg University
  • ,
  • Bjarne Kuno Møller
  • Torben Barington, University of Southern Denmark

Identification of risk factors for contracting and developing serious illness following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of paramount interest. Here, we performed a retrospective cohort analysis of all Danish individuals tested for SARS-CoV-2 between 27 February 2020 and 30 July 2020, with a known ABO and RhD blood group, to determine the influence of common blood groups on virus susceptibility. Distribution of blood groups was compared with data from nontested individuals. Participants (29% of whom were male) included 473 654 individuals tested for SARS-CoV-2 using real-time polymerase chain reaction (7422 positive and 466 232 negative) and 2 204 742 nontested individuals, accounting for ∼38% of the total Danish population. Hospitalization and death from COVID-19, age, cardiovascular comorbidities, and job status were also collected for confirmed infected cases. ABO blood groups varied significantly between patients and the reference group, with only 38.41% (95% confidence interval [CI], 37.30-39.50) of the patients belonging to blood group O compared with 41.70% (95% CI, 41.60-41.80) in the controls, corresponding to a relative risk of 0.87 (95% CI, 0.83-0.91) for acquiring COVID-19. This study identifies ABO blood group as a risk factor for SARS-CoV-2 infection but not for hospitalization or death from COVID-19.

Original languageEnglish
JournalBlood Advances
Volume4
Issue20
Pages (from-to)4990-4993
Number of pages4
ISSN2473-9529
DOIs
Publication statusPublished - Oct 2020

See relations at Aarhus University Citationformats

ID: 201382622